{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:41:02Z","timestamp":1790905262925,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jns.2020.116740","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T21:45:13Z","timestamp":1582062313000},"page":"116740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Initial deterioration and intravenous methylprednisolone therapy in patients with myasthenia gravis"],"prefix":"10.1016","volume":"412","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3652-0772","authenticated-orcid":false,"given":"Takamichi","family":"Sugimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Tazuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Mine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0990-1385","authenticated-orcid":false,"given":"Eiichi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Kohriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takemori","family":"Yamawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2020.116740_bb0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000322497","article-title":"Early aggressive treatment strategy against myasthenia gravis","volume":"65","author":"Nagane","year":"2011","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.jns.2020.116740_bb0010","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/mus.25397","article-title":"Early fast-acting treatment strategy against generalized myasthenia gravis","volume":"55","author":"Utsugisawa","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2020.116740_bb0015","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/jnnp.68.2.214","article-title":"Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis","volume":"68","author":"Komiyama","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2020.116740_bb0020","first-page":"121","article-title":"Treatment of ocular myasthenia gravis with steroid pulse therapy (in Japanese)","volume":"23","author":"Kurimoto","year":"2006","journal-title":"Atarashii Ganka (J. Eye)"},{"key":"10.1016\/j.jns.2020.116740_bb0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2019.05.003","article-title":"Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis","volume":"402","author":"Ozawa","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2020.116740_bb0030","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/archneur.1985.04060110031011","article-title":"High-dose intravenous methylprednisolone in myasthenia gravis","volume":"42","author":"Arsura","year":"1985","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2020.116740_bb0035","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","article-title":"Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study","volume":"97","author":"Lindberg","year":"1998","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jns.2020.116740_bb0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cen3.12180","article-title":"Japanese clinical guidelines for myasthenia gravis: putting into practice","volume":"6","author":"Murai","year":"2014","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.jns.2020.116740_bb0045","first-page":"16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the Myasthenia Gravis Foundation of America Neurology","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2020.116740_bb0050","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2020.116740_bb0055","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jns.2018.10.018","article-title":"Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis","volume":"396","author":"Kanai","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2020.116740_bb0060","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/j.1552-4604.1994.tb01988.x","article-title":"Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers","volume":"34","author":"Ferry","year":"1994","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jns.2020.116740_bb0065","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1212\/01.WNL.0000138572.82125.F5","article-title":"The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis","volume":"63","author":"Morrow","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2020.116740_bb0070","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jns.2020.116740_bb0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0022-510X(98)00031-8","article-title":"Exacerbation of myasthenia gravis during the menstrual period","volume":"156","author":"Leker","year":"1998","journal-title":"J. Neurol. Sci."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20300769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20300769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:50:12Z","timestamp":1758383412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X20300769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":15,"alternative-id":["S0022510X20300769"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2020.116740","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initial deterioration and intravenous methylprednisolone therapy in patients with myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2020.116740","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116740"}}